Hong Kong stock market abnormal | Waising Pharmaceuticals-B(02561.HK) rose more than 5% The drug Navelpatide for treating cartilage dysplasia completed phase 2 clinical trials in China.

According to the WiseWealth Financial News APP, Uni-Bio Science Group Limited (02561.HK) has risen by over 5%, as of the time of publication, up 5.39% to HK$46.9, with a trading volume of HK$2.1721 million.